SNAP-8 (Acetyl Octapeptide-3)
Evidence: DDermatology / Cosmetic Research
Evidence Snapshot
What this grade covers
A for chemical identity; C for formulation-specific topical cosmetic studies; D/E for isolated-monotherapy efficacy, botulinum-toxin equivalence, injected use, muscle paralysis, drug approval, or dosing claims.
Regulatory Context
SNAP-8 is used as a cosmetic ingredient. No FDA-approved SNAP-8 drug product was identified. Cosmetic-product registration, cosmetic use, or MoCRA compliance does not constitute FDA approval of SNAP-8 as a drug or establish therapeutic efficacy.
In Plain English
A quick, research-focused overview. It does not replace, and cannot outrank, the detailed evidence below.
What is it?
SNAP-8 is a synthetic acetylated octapeptide used in cosmetic formulations. Human studies located evaluated multi-ingredient formulations containing acetyl octapeptide-3 -- a hyaluronic-acid microneedle patch, a dissolving microneedle patch also containing a vitamin-C derivative, and a proprietary multi-ingredient serum -- none isolated the contribution of SNAP-8 itself.
Why are researchers interested in it?
It is studied in cosmetic formulation, analytical quality-control, skin-delivery, and anti-wrinkle product research.
What does the evidence look like?
Evidence grade D. Human, preclinical, regulatory, review, and anecdotal evidence must remain separated.
Biggest things to know
Keep it distinct from Argireline/acetyl hexapeptide-8. Common quantitative wrinkle claims were not verified in an independent, compound-only controlled trial.
Research Takeaway
SNAP-8 (Acetyl Octapeptide-3) is represented under the canonical identity Acetyl octapeptide-3; listed aliases refer to this identity unless a formulation-specific distinction is stated.
See all 9 evidence claims →Quick Summary
SNAP-8 is the cosmetic ingredient Acetyl Octapeptide-3. Human studies identified evaluated multi-ingredient topical or microneedle formulations, not isolated SNAP-8 monotherapy, so the peptide's individual contribution cannot be determined. SNAP-8 is distinct from Acetyl Hexapeptide-8/Argireline, and neither cosmetic evidence nor mechanism proposals establish injectable, systemic, drug-like, or botulinum-toxin-equivalent effects.
Mechanism & Research Overview
Acetyl Octapeptide-3 is proposed to influence SNARE/SNAP-25-related signaling in cosmetic applications. The mechanism is not established as clinically equivalent to botulinum toxin, and finished-product studies do not isolate SNAP-8's independent effect. Argireline/Acetyl Hexapeptide-8 is a separate peptide and must remain an evidence-boundary source only.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
SNAP-8 (Acetyl Octapeptide-3) is represented under the canonical identity Acetyl octapeptide-3; listed aliases refer to this identity unless a formulation-specific distinction is stated.
Sources: Acetyl octapeptide-3 compound record
Supported
Human studies located evaluated multi-ingredient formulations containing acetyl octapeptide-3 -- a hyaluronic-acid microneedle patch, a dissolving microneedle patch also containing a vitamin-C derivative, and a proprietary multi-ingredient serum -- none isolated the contribution of SNAP-8 itself.
Sources: Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: a monocentric clinical study; Clinical Safety and Efficacy Evaluation of a Dissolving Anti-wrinkle Microneedle Patch; Peptide-pro complex serum: Investigating effects on aged skin
Supported
The main safety limitations for SNAP-8 (Acetyl Octapeptide-3) include Compound-specific clinical safety data are limited.
Sources: Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: a monocentric clinical study; Clinical Safety and Efficacy Evaluation of a Dissolving Anti-wrinkle Microneedle Patch; Peptide-pro complex serum: Investigating effects on aged skin
Supported
Cosmetic ingredient/research peptide; no FDA-approved SNAP-8 drug product was identified. Cosmetic-product studies do not establish approval or therapeutic efficacy.
Sources: Acetyl octapeptide-3 compound record
Supported
SNAP-8 is a trade/development name for Acetyl Octapeptide-3, a synthetic acetylated octapeptide (sequence Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp with N-terminal acetylation) used in topical cosmetic formulations. It must remain separate from Acetyl Hexapeptide-8/Argireline, Acetyl Hexapeptide-3, SNAP-25 protein, botulinum toxin type A products, Acetyl Octapeptide-1 unless analytical identity is confirmed, palmitoylated peptides, collagen-derived octapeptides, multi-peptide cosmetic blends, and proprietary finished products containing SNAP-8 plus other actives.
Sources: Acetyl octapeptide-3 compound record; A synthetic hexapeptide (Argireline) with antiwrinkle activity
Supported
SNAP-8 was designed as a longer analogue of the acetyl-hexapeptide cosmetic class and is proposed to mimic a region of SNAP-25 involved in SNARE-complex assembly. This mechanism has major limitations: topical skin penetration and peptide stability are formulation dependent, laboratory SNARE interference does not prove muscle paralysis, cosmetic wrinkle appearance is not equivalent to chemodenervation, and botulinum toxins cleave SNARE proteins through a fundamentally different enzymatic mechanism. SNAP-8 must not be called topical Botox or an equivalent to an FDA-approved botulinum toxin.
Supported
Studies of Acetyl Hexapeptide-8/Argireline cannot be assigned to Acetyl Octapeptide-3/SNAP-8. Multi-ingredient anti-aging serums containing SNAP-8 alongside growth factors, hyaluronic acid, niacinamide, other peptides, antioxidants, retinoids, or moisturizers cannot establish SNAP-8-specific efficacy. No adequate, independently replicated, randomized monotherapy trial of isolated SNAP-8 was identified that establishes clinically meaningful wrinkle reduction attributable solely to SNAP-8, neuromuscular blockade, muscle paralysis, equivalence to botulinum toxin, durable structural skin change, efficacy after injection, safe microneedling or transdermal-device use, or long-term repeated-use safety.
Sources: A synthetic hexapeptide (Argireline) with antiwrinkle activity; Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: a monocentric clinical study; Clinical Safety and Efficacy Evaluation of a Dissolving Anti-wrinkle Microneedle Patch
Supported
No FDA-approved SNAP-8 or Acetyl Octapeptide-3 drug product or indication was identified. In the United States, ordinary cosmetics and cosmetic ingredients are generally not preapproved by FDA before marketing; cosmetics must be safe under labeled or customary conditions of use, and claims to treat disease or affect body structure/function -- including muscle paralysis, neuromuscular blockade, collagen production, tissue remodeling, or treatment of wrinkles -- may create drug intended use depending on context. Commercial cosmetic availability under MoCRA is not drug approval.
Sources: FDA Modernization of Cosmetics Regulation Act Overview; FDA Wrinkle Treatments and Other Anti-Aging Products; FDA Cosmetic Versus Drug Intended-Use Guidance
Supported
Topical cosmetic use appears to have limited reported serious toxicity in small finished-product studies, but isolated-ingredient safety is not fully characterized. Important uncertainties include irritation and contact sensitization, formulation pH and preservative effects, peptide degradation or oxidation, impurities and synthesis byproducts, microbial contamination, skin penetration variability, enhanced systemic exposure after microneedling or barrier disruption, infection or scarring from home microneedling, ocular exposure in periocular use, unknown pregnancy/pediatric/chronic/immunogenicity/systemic safety, unverified identity or concentration in marketplace products, and differences between cosmetic-grade and injectable-grade claims. A cosmetic ingredient should not be injected.
Sources: Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: a monocentric clinical study; Clinical Safety and Efficacy Evaluation of a Dissolving Anti-wrinkle Microneedle Patch
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Compound-specific clinical safety data are limited.Safety Consideration
Microneedle and topical formulations have route-, device-, and co-ingredient-specific risks.Safety Consideration
Multi-ingredient product studies cannot establish the efficacy or safety of SNAP-8 alone.Safety Consideration
Irritation and contact sensitization, formulation pH and preservative effects, peptide degradation or oxidation, impurities and synthesis byproducts, microbial contamination, skin penetration variability, enhanced systemic exposure after microneedling or barrier disruption, infection or scarring from home microneedling, ocular exposure in periocular use, unverified identity/concentration in marketplace products, and differences between cosmetic-grade and injectable-grade claims all remain uncertain. Pregnancy, pediatric, chronic, immunogenicity, and systemic safety are unknown. A cosmetic ingredient should not be injected.
Research Areas Being Studied
Research areas discussed on this page reflect the Dermatology / Cosmetic Research category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Clinical Safety and Efficacy Evaluation of a Dissolving Anti-wrinkle Microneedle Patch (2024):
- Peptide-pro complex serum: Investigating effects on aged skin (2023):
- Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: a monocentric clinical study (2020):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Clinical Safety and Efficacy Evaluation of a Dissolving Anti-wrinkle Microneedle Patch | 2024 | Clinical evaluation of a multi-component dissolving microneedle patch | A patch containing hyaluronic acid, acetyl octapeptide-3, vitamin-C derivative, and other formulation elements improved selected wrinkle endpoints. | Cannot isolate the effect of acetyl octapeptide-3; device and co-ingredient effects are inseparable. | |
| Peptide-pro complex serum: Investigating effects on aged skin | 2023 | Ex vivo skin testing and a 12-week open-label clinical study of a proprietary multi-ingredient serum | The proprietary serum improved selected skin-appearance endpoints in ex vivo and clinical assessments. | The formula contained a blend of neuropeptides, proteins, amino acids, and marine extracts; it does not isolate SNAP-8. | |
| Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: a monocentric clinical study | 2020 | Participants using a multi-ingredient hyaluronic-acid microneedle patch for 12 weeks | The multi-ingredient patch, which included acetyl octapeptide-3 and other actives, improved selected cosmetic endpoints. | The formulation contained multiple active ingredients, so SNAP-8-specific efficacy and safety cannot be isolated. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry | 2020 | Analytical method and biodegradable microneedle-patch application | Developed and applied an LC-MS/MS method for quantifying SNAP-8 in a microneedle patch. | Analytical validation is not evidence of anti-wrinkle clinical efficacy or systemic safety. | |
| A synthetic hexapeptide (Argireline) with antiwrinkle activity | 2002 | Biochemical/cellular studies and cosmetic context for acetyl hexapeptide | This foundational Argireline study supports related SNAP-25/SNARE cosmetic-peptide biology but evaluates a different hexapeptide. | Do not assign Argireline efficacy, safety, or identity directly to SNAP-8. Argireline and SNAP-8 are distinct compounds from the same developer's product family. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Acetyl octapeptide-3 compound record | 2026 | Chemical identity database record | PubChem identifies acetyl octapeptide-3 and reports its sequence-related name and molecular formula. | Chemical identity does not establish cosmetic efficacy or drug approval. | |
| FDA Cosmetic Versus Drug Intended-Use Guidance | FDA guidance on distinguishing cosmetic from drug intended use: a product's intended use (as shown by claims) determines whether it is regulated as a cosmetic, a drug, or both, independent of ingredient identity. Shared reference for both AHK-Cu and SNAP-8. | ||||
| FDA Modernization of Cosmetics Regulation Act Overview | The FDA's Modernization of Cosmetics Regulation Act (MoCRA) overview describes updated cosmetic facility registration, product listing, safety substantiation, and adverse-event reporting requirements. MoCRA does not create a premarket drug-approval requirement for ordinary cosmetic ingredients such as SNAP-8, and commercial cosmetic availability under MoCRA is not equivalent to FDA drug approval. | ||||
| FDA Wrinkle Treatments and Other Anti-Aging Products | FDA does not preapprove cosmetic ingredients or ordinary cosmetics before marketing. Claims that a topical product changes skin structure/function, increases collagen production, treats disease, or otherwise affects body function may make it a drug claim requiring approval. Shared reference for both AHK-Cu and SNAP-8 -- the FDA page does not name either compound specifically, it establishes the general cosmetic-claims regulatory boundary both pages rely on. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Cosmeceutical Peptides and SNAP-8 Mechanism Review | A review of cosmeceutical peptides situates SNAP-8 as a longer analogue of the acetyl-hexapeptide cosmetic class, proposed to mimic a region of SNAP-25 involved in SNARE-complex assembly. The review notes major limitations: topical skin penetration and peptide stability are formulation dependent, laboratory SNARE interference does not prove muscle paralysis, cosmetic wrinkle appearance is not equivalent to chemodenervation, and botulinum toxins cleave SNARE proteins through a fundamentally different enzymatic mechanism than any proposed cosmetic-peptide effect. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
This page concerns cosmetic/topical Acetyl Octapeptide-3. Finished-product, microneedle-device, and multi-ingredient studies are formulation-specific and cannot establish the efficacy or safety of isolated SNAP-8. The page does not support injection, systemic administration, treatment, or dosing.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-30.
Follow research updates for SNAP-8 (Acetyl Octapeptide-3)
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.